Devonian Health Group Inc. (CVE:GSD – Get Free Report) shares fell 23.5% during mid-day trading on Friday . The company traded as low as C$0.09 and last traded at C$0.13. 119,000 shares traded hands during trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Stock Down 23.5%
The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36. The business’s 50-day simple moving average is C$0.16 and its 200-day simple moving average is C$0.17. The company has a market capitalization of C$19.27 million, a PE ratio of -4.64 and a beta of 0.67.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Recommended Stories
- Five stocks we like better than Devonian Health Group
- Most active stocks: Dollar volume vs share volume
- Tesla: 2 Reasons to Love Musk’s $1B Buy, 1 Reason to Be Bearish
- What is a support level?
- Azure Leads While AI Excitement Fuels Microsoft Stock
- 3 Fintech Stocks With Good 2021 Prospects
- Darden Restaurants: A Textbook Buy-the-Dip Opportunity
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
